

Angina pectoris - Pipeline Insight, 2021

<https://marketpublishers.com/r/ADEC1D95EE2EN.html>

Date: June 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: ADEC1D95EE2EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Angina pectoris - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Angina pectoris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Angina pectoris Understanding

Angina pectoris: Overview

Angina pectoris is the medical term for chest pain or discomfort due to coronary heart disease. It occurs when the heart muscle doesn't get as much blood as it needs. This usually happens because one or more of the heart's arteries is narrowed or blocked, also called ischemia. Chest pain is the symptom, but it affects people differently. People may also experience: Aching, Burning, Discomfort, Dizziness, Fatigue, Feeling of fullness in your chest, Feeling of heaviness or pressure, Upset stomach or vomiting, Shortness of breath, Squeezing, Sweating. There are different types of angina:

Stable angina: This is the most common. Physical activity or stress can trigger it. It usually lasts a few minutes, and it goes away on rest.

Unstable angina: This occurs at rest or not very active. The pain can be strong and long-lasting, and it may come back again and again.

Microvascular angina: Chest pain but no coronary artery blockage.

Prinzmetal's angina (variant angina): This type is rare. It might happen at night while sleeping or resting.

People with angina pectoris or sometimes referred to as stable angina have episodes of chest pain. The discomfort that are usually predictable and manageable. Normally this type of chest discomfort is relieved with rest, nitroglycerin or both. Nitroglycerin relaxes the coronary arteries and other blood vessels, reducing the amount of blood that returns to the heart and easing the heart's workload. By relaxing the coronary arteries, it increases the heart's blood supply.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Angina pectoris R&D. The therapies under development are focused on novel approaches for Angina pectoris.

Angina pectoris Emerging Drugs Chapters

This segment of the Angina pectoris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Angina pectoris Emerging Drugs

CLBS14: Caladrius Biosciences

CLBS14 is a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”). It is being developed by Caladrius Biosciences.

IMB-101: Imbria pharmaceuticals

IMB-101 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease. As a partial fatty acid oxidation (pFOX) inhibitor, IMB-101 is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed thereby increasing myocardial metabolic efficiency.

It is currently in Phase II stage of development for Angina pectoris and is being developed by Imbria pharmaceuticals.

Further product details are provided in the report..

Angina pectoris: Therapeutic Assessment

This segment of the report provides insights about the different Angina pectoris drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Angina pectoris

There are approx. 5+ key companies which are developing the Angina pectoris. The companies which have their Angina pectoris drug candidates in the most advanced stage, i.e. Phase III include, Caladrius Biosciences.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Angina pectoris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Angina pectoris: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Angina pectoris therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angina pectoris drugs.

Angina pectoris Report Insights

Angina pectoris Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Angina pectoris Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Angina pectoris drugs?

How many Angina pectoris drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Angina pectoris?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Angina pectoris therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Angina pectoris and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Imbria pharmaceuticals

Arbor Pharmaceuticals

Caladrius Biosciences

XyloCor Therapeutics

Key Products

IMB101

AR36

CLBS 14

XC-001

Contents

Introduction

Executive Summary

Angina pectoris: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Angina pectoris– DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Angina pectoris companies' collaborations, Licensing, Acquisition -Deal Value Trends

Angina pectoris Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

AR36: Arbor Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

IMB-101: Imbria pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Early Stage Products (Phase I/II)

Comparative Analysis

XC-001: XyloCor Therapeutics

Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..

Inactive Products
Comparative Analysis
Angina pectoris Key Companies
Angina pectoris Key Products
Angina pectoris- Unmet Needs
Angina pectoris- Market Drivers and Barriers
Angina pectoris- Future Perspectives and Conclusion
Angina pectoris Analyst Views
Angina pectoris Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Angina pectoris
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Angina pectoris
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Angina pectoris - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/ADEC1D95EE2EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ADEC1D95EE2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970